Rvl Pharmaceuticals Plc (RVLP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2017 | 12-2016 | 12-2006 | |
| Cash Flows From Operating Activities | |||
| Net Income | -41,142 | -41,821 | N/A |
| Depreciation Amortization | 119,436 | 45,060 | N/A |
| Income taxes - deferred | -48,507 | -13,162 | N/A |
| Accounts receivable | 5,269 | -12,526 | N/A |
| Accounts payable and accrued liabilities | 588 | -14,390 | N/A |
| Other Working Capital | 9,487 | -46,326 | N/A |
| Other Operating Activity | 12,706 | 38,374 | 0 |
| Operating Cash Flow | $57,837 | $-44,791 | $N/A |
| Cash Flows From Investing Activities | |||
| PPE Investments | -6,895 | -13,931 | N/A |
| Net Acquisitions | -12,500 | -437,532 | N/A |
| Purchase Sale Intangibles | N/A | -2,000 | N/A |
| Other Investing Activity | 0 | -2,000 | 0 |
| Investing Cash Flow | $-19,395 | $-453,463 | $N/A |
| Cash Flows From Financing Activities | |||
| Debt Issued | 327,500 | 342,500 | N/A |
| Debt Repayment | -347,379 | -4,264 | N/A |
| Other Financing Activity | -3,436 | 82,280 | 0 |
| Financing Cash Flow | $-23,314 | $420,516 | $N/A |
| Exchange Rate Effect | 57 | -316 | N/A |
| Beginning Cash Position | 19,559 | 97,612 | N/A |
| End Cash Position | 34,743 | 19,559 | N/A |
| Net Cash Flow | $15,185 | $-78,053 | $N/A |
| Free Cash Flow | |||
| Operating Cash Flow | 57,837 | -44,791 | N/A |
| Capital Expenditure | -6,895 | -13,931 | N/A |
| Free Cash Flow | 50,942 | -58,722 | 0 |